- Company
- Will Trodelvy be deliberated for reimb by DREC in August?
- by Eo, Yun-Ho Jul 11, 2024 05:47am
- The road to reimbursement for the new ADC breast cancer drug Troldelvy remains a bumpy one. The agenda remains pending for 8 months now. Gilead Sciences' triple-negative breast cancer (TNBC) drug Troldelvy, whose reimbursement request received 100,000 consents in a public petition, was not presented for deliberation to the Health Insuranc
- Policy
- Simulect in supply crisis with no alternative
- by Lee, Tak-Sun Jul 11, 2024 05:47am
- Simulect Inj (basiliximab, Novartis Korea), which is used as an induction therapy to prevent immune rejection in organ transplant patients, is expected to run out of supply in Korea due to issues in securing the supply the drug’s active pharmaceutical ingredient. In particular, there is no alternative drug for liver transplantation, in
- Company
- From obesity to brain diseases...expansion of GLP-1 agonists
- by Son, Hyung-Min Jul 11, 2024 05:46am
- The domestic pharmaceutical bio industry is looking into the possibility of developing various new drugs with GLP-1 agents. As Novo Nordisk and Lilly's GLP-1-based obesity drugs have become global blockbusters, latecomers are also avidly developing jumping in to develop the next blockbuster. Major domestic companies are conducting clinical s
- Policy
- Debate within the Health and Welfare Committee members
- by Lee, Jeong-Hwan Jul 10, 2024 05:48am
- Members of the Democratic Party of Korea and the ruling party who are also committee members of the Health and Welfare Committee of the National Assembly show significant differences in viewpoints regarding President Yoon Suk Yeol’s policy of expanding medical school quotas, and the current situation surrounding the conflict between the med
- InterView
- ‘Ireland, a bridgehead for companies entering the EU mkt'
- by Nho, Byung Chul Jul 10, 2024 05:48am
- "Ireland has the best condition for multinational pharmaceutical and biotech companies to invest and operate in as a bridgehead to the European market." Rory Mullen, Global Head of Biopharma and Food at Investment Promotion & Development Agency Ireland explained so during his recent visit to South Korea. Mr. Mullen visited Korea to discus
- Company
- GC Biopharma ships first batch of ‘Alyglo’ to the U.S.
- by Son, Hyung-Min Jul 10, 2024 05:48am
- GC Biopharma announced on the 8th that it has completed the shipment of the first batch of its blood product ‘Alyglo’, which was approved by the U.S. Food and Drug Administration (FDA) late last year. The shipment will be delivered to specialized pharmacies through warehouses and distributors in the U.S. and is expected to be available f
- Policy
- Reimbursement application submitted for 'Adempas tab'
- by Lee, Tak-Sun Jul 10, 2024 05:48am
- Bayer’s 'Adempas tab,' a treatment for chronic thromboembolic pulmonary hypertension (CTEPH), is being considered for reimbursement listing 10 years after its approval as a novel drug. According to industry sources on July 2nd, a reimbursement decision application for Adempas was recently submitted to the Health Insurance Review and Ass
- Company
- Tecentriq reapplies for reimb in early stage NSCLC
- by Eo, Yun-Ho Jul 10, 2024 05:48am
- The immuno-oncology drug Tecentriq is reattempting to expand insurance reimbursement to early-stage lung cancer. According to Dailypharm coverage, Roche Korea's PD-L1 inhibitor Tecentriq (atezolizumab) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee today (July 10). The s
- Company
- With Lixiana and Enhertu, Daiichi-Sankyo’s sales growth↑
- by Hwang, Byung-woo Jul 9, 2024 06:07am
- Daiichi-Sankyo Korea has achieved continuous sales growth over the past five years with Enhertu (ingredient: trastuzumab deruxtecan) and Lixiana (ingredient: edoxaban). Last year, it recorded sales of KRW 274 billion, nearing sales of KRW 300 billion. Its operating benefit also topped its peak over the past five years. Japan-based pharmac
- Company
- Industry struggles to develop new atopic dermatitis drugs
- by Son, Hyung-Min Jul 9, 2024 05:51am
- The domestic pharmaceutical bio-industry is facing difficulties in developing new drugs for atopic dermatitis. Recently, Kangstem Biotech's stem cell therapy drug completed Phase III clinical trials, but the results fell short of expectations. JW Pharmaceutical's atopic dermatitis drug candidate failed to prove its efficacy in a Phase II clinica
